Vanda article praises firm's lipid-lowerer

16 March 2009

Vanda Pharmaceuticals reports the publication of an article recommeding its drug candidate iloperidone in Schizophrenia Research, the official  journal of the Schizophrenia International Research Society,

The manuscript, entitled Common Effect of Antipsychotics on the  Biosynthesis and Regulation of Fatty Acids and Cholesterol Supports a  Key Role of Lipid Homeostasis in Schizophrenia, highlights the discovery  of a major effect of antipsychotics that the firm says sheds new light  on how the drugs work.

Vanda researchers analyzed the mechanism of action of 18 antipsychotics  at the molecular level and discovered that they regulate specific genes  that control the production and transport of lipids. These findings  suggest that antipsychotic drugs may alter the fluidity of cell  membranes of neurons, which could result in changes in neuronal  connectivity.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight